Cash B D, Chey W D
Division of Gastroenterology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Aliment Pharmacol Ther. 2004 Jun 15;19(12):1235-45. doi: 10.1111/j.1365-2036.2004.02001.x.
Irritable bowel syndrome (IBS) represents one of the most common reasons for primary care visits and consultation with a gastroenterologist. It is characterized by abdominal discomfort, bloating and disturbed defecation in the absence of any identifiable physical, radiologic or laboratory abnormalities indicative of organic gastrointestinal disease. IBS is a costly disorder, responsible for significant direct and indirect costs to patients and society. Much of the cost attributed to IBS arises from the time and resources used to establish the diagnosis. Historically IBS has been viewed by many as a diagnosis of exclusion rather than as a primary diagnosis, and many patients with typical symptoms will undergo an extensive array of diagnostic tests and procedures prior to the eventual diagnosis of IBS. Recent reviews addressing the management of such patients have cast doubt on the necessity for this degree of testing. Current best evidence does not support the routine use of blood tests, stool studies, breath tests, abdominal imaging or lower endoscopy in order to exclude organic gastrointestinal disease in patients with typical IBS symptoms without alarm features. Serological testing for celiac sprue in this population may eventually prove useful but validation of studies indicating an increased prevalence of this disease in patients with suspected IBS is needed. The development and refinement of symptom-based criteria defining the clinical syndrome of IBS has greatly facilitated the diagnosis of this condition, which can be confidently diagnosed through the identification of typical symptoms, normal physical examination and the exclusion of alarm features. The presence of alarm features or persistent non-response to symptom-directed therapies should prompt a more detailed diagnostic evaluation dictated by the patient's predominant symptoms.
肠易激综合征(IBS)是基层医疗就诊及咨询胃肠病专家的最常见原因之一。其特征为腹部不适、腹胀及排便紊乱,且不存在任何可表明存在器质性胃肠疾病的可识别的体格检查、影像学或实验室异常。IBS是一种代价高昂的疾病,给患者和社会带来了巨大的直接和间接成本。IBS的许多成本源于用于确诊的时间和资源。从历史上看,许多人将IBS视为一种排除性诊断而非原发性诊断,许多有典型症状的患者在最终被诊断为IBS之前会接受一系列广泛的诊断测试和程序。最近针对此类患者管理的综述对这种程度的检测的必要性提出了质疑。目前的最佳证据不支持对没有警示特征的典型IBS症状患者常规使用血液检查、粪便检查、呼气试验、腹部影像学检查或下消化道内镜检查来排除器质性胃肠疾病。对该人群进行乳糜泻的血清学检测最终可能会证明有用,但需要对表明疑似IBS患者中该病患病率增加的研究进行验证。基于症状的标准的制定和完善,定义了IBS的临床综合征,极大地促进了该病的诊断,通过识别典型症状、正常体格检查及排除警示特征可自信地做出诊断。出现警示特征或对针对症状的治疗持续无反应,应根据患者的主要症状进行更详细的诊断评估。